Panion & Bf Biotech Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Panion & Bf Biotech heeft een totaal eigen vermogen van NT$1.9B en een totale schuld van NT$725.6M, wat de schuld-eigenvermogensverhouding op 39.1% brengt. De totale activa en totale passiva bedragen respectievelijk NT$3.3B en NT$1.4B. De EBIT Panion & Bf Biotech is NT$193.4M waardoor de rentedekking 207 is. Het heeft contanten en kortetermijnbeleggingen van NT$581.9M.

Belangrijke informatie

39.1%

Verhouding schuld/eigen vermogen

NT$725.56m

Schuld

Rente dekkingsratio	207x
Contant	NT$581.86m
Aandelen	NT$1.85b
Totaal verplichtingen	NT$1.40b
Totaal activa	NT$3.25b

Recente financiële gezondheidsupdates

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( NT$1.5B ) 1760 } overtreffen de korte termijn passiva ( NT$1.1B ).

Langlopende schulden: De kortetermijnactiva 1760 ( NT$1.5B ) overtreffen de langetermijnschulden ( NT$272.0M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 7.8% ) 1760 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 1760 is de afgelopen 5 jaar gestegen van 0% naar 39.1%.

Schuldendekking: De schuld van 1760 wordt goed gedekt door de operationele kasstroom ( 40.7% ).

Rentedekking: De rentebetalingen op de schuld van 1760 worden goed gedekt door EBIT ( 207 x dekking).

Panion & Bf Biotech Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Recent updates

Panion & Bf Biotech Inc. to Report Q3, 2024 Results on Nov 12, 2024

Second quarter 2024 earnings released: EPS: NT$0.23 (vs NT$0.20 in 2Q 2023)

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Panion & Bf Biotech Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.50 per share

Panion & Bf Biotech Inc. Announces the Cash Dividend, Payable on July 10, 2024

Panion & Bf Biotech Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.90 (vs NT$2.13 in FY 2022)

Panion & Bf Biotech Inc., Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Panion and BF Biotech Inc. Obtains Nephoxil NDA Approval

Panion & Bf Biotech Inc. Announces Nephoxil Receives NMPA Acceptance for NDA Application Submission

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$1.88 in 2Q 2022)

Upcoming dividend of NT$2.00 per share at 1.5% yield

Panion & Bf Biotech Inc. Announces the Cash Dividend, payable on August 11, 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.32 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.91 (vs NT$0.77 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.88 (vs NT$0.97 in 2Q 2021)

Upcoming dividend of NT$1.50 per share

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: NT$0.46 (vs NT$0.32 loss in 1Q 2021)

Price target increased to NT$106

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.77 (vs NT$0.038 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.97 (vs NT$0.099 loss in 2Q 2020)

Upcoming dividend of NT$0.70 per share

Price target increased to NT$108

First quarter 2021 earnings released: NT$0.32 loss per share (vs NT$0.009 profit in 1Q 2020)

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS NT$0.36 (vs NT$2.10 in FY 2019)

Panion & Bf Biotech Inc., Annual General Meeting, Jun 04, 2021

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

New 90-day low: NT$74.10

Price target lowered to NT$97.00

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

New 90-day low: NT$80.60

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

New 90-day low: NT$91.10

Third quarter 2020 earnings released: NT$0.04 loss per share

Revenue misses expectations

New 90-day low: NT$104

New 90-day low: NT$112

Price target raised to NT$141

First half earnings released

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven